AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The primary objective is to define the safety and tolerability of AB8939 in patients with AML
by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended
dose for dose expansion study.